Salarius Pharmaceuticals Inc (SLRX)

$0.64 -0.02 (-2.48%)
Market Cap 3.82M
Revenue (ttm) 0.00
Net Income (ttm) -5.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 111,400
Avg Vol 2,199,286
Day's Range N/A - N/A
Shares Out 5.86M
Stochastic %K 6%
Beta 0.40
Analysts Hold
Price Target $26.00

Company Profile

Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a port...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 913 5608
Address:
2450 Holcombe Blvd., Suite X, Houston, United States
jsmith14
jsmith14 Dec. 24 at 9:42 PM
$SLRX Santa Claus is coming to town!
0 · Reply
ABAdude
ABAdude Dec. 24 at 7:01 PM
$SLRX Hang in there longs. There is zero real capitulation occurring. Cost basis must move and profited shares ⬆️ . These are a couple of indicators that would show that real holders are selling and new buyers absorbing shares, thus lowering the cost basis. 😉
0 · Reply
Eddie5150
Eddie5150 Dec. 24 at 6:21 PM
$SLRX
0 · Reply
ABAdude
ABAdude Dec. 24 at 4:25 PM
$SLRX The 2nd image represents how most holders are underwater and would be selling for major losses on a daily basis, as this stock has been selling off daily. This appears more like MM selling shares they don’t own fo liquidity. This will show as outflow, not longs exiting (“The Game”) Short sales - short exempt orders - internal dark pool trades count as outflow immediately. While any inflow from retail is fragmented, happens in small orders, not fully registering as inflow; therein lies the illusion of selling, though it’s all synthetic and not holder capitulation. If this was a bearish indication and a sign of organic selling, the cost basis would shift downward and profited share % would rise. 🤔 Do we see this?? No! So many signs that indicate MMs attempting to control the narrative, but their actions soak differently to those who get it 🧠. Informations purposes only!
2 · Reply
ABAdude
ABAdude Dec. 23 at 5:55 PM
$SLRX Just dropping this off here. Thought some may be interested to see this stat and how it’s not being reflected in the price action. High CTB, low float, manipulated price action. 🤔
0 · Reply
Skywalker86
Skywalker86 Dec. 23 at 3:52 PM
$SLRX CTB 627% | only 95k shares available | ~5.8M float Top-10 highest borrow on ChartExchange. This is the same supply squeeze setup $AFJK before its +130% rip. Shorts paying 600%+ with no borrow cushion = any volume spike can force cover.
2 · Reply
doubleyou2
doubleyou2 Dec. 23 at 2:21 PM
$SLRX 627% !!
0 · Reply
UpWeGo11
UpWeGo11 Dec. 23 at 12:25 AM
$SLRX all them 6s do something then
0 · Reply
jeco
jeco Dec. 22 at 6:09 PM
$SLRX Borrow Fee has gone back up! 🤔
1 · Reply
doubleyou2
doubleyou2 Dec. 22 at 5:53 PM
$SLRX Sell now -> Cry later. No balls, no glory.
1 · Reply
Latest News on SLRX
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Dec 19, 2025, 11:12 AM EST - 5 days ago

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Dec 18, 2025, 7:50 AM EST - 6 days ago

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Dec 1, 2025, 8:00 AM EST - 23 days ago

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Nov 19, 2025, 2:42 PM EST - 5 weeks ago

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Nov 13, 2025, 8:45 AM EST - 5 weeks ago

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Nov 11, 2025, 9:18 AM EST - 6 weeks ago

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Oct 13, 2025, 8:45 AM EDT - 2 months ago

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 9, 2025, 8:00 AM EDT - 3 months ago

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Aug 14, 2025, 8:30 AM EDT - 4 months ago

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Jul 14, 2025, 8:30 AM EDT - 5 months ago

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Jul 9, 2025, 8:30 AM EDT - 6 months ago

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Apr 16, 2025, 8:00 AM EDT - 9 months ago

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Mar 24, 2025, 8:00 AM EDT - 9 months ago

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Feb 3, 2025, 8:00 AM EST - 11 months ago

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Jan 13, 2025, 2:12 PM EST - 1 year ago

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 22, 2024, 4:05 PM EDT - 1 year ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Jan 3, 2024, 8:30 AM EST - 2 years ago

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Nov 7, 2023, 8:30 AM EST - 2 years ago

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 16, 2023, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 12, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

May 9, 2023, 8:17 AM EDT - 2 years ago

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

May 9, 2023, 8:00 AM EDT - 2 years ago

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

May 1, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Apr 20, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Apr 4, 2023, 4:02 PM EDT - 2 years ago

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 27, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Mar 15, 2023, 11:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Feb 16, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 27, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 19, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Dec 13, 2022, 8:01 AM EST - 3 years ago

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Dec 13, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Dec 1, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Nov 3, 2022, 9:57 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 27, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 19, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Oct 18, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

Oct 14, 2022, 8:43 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Sep 20, 2022, 12:00 PM EDT - 3 years ago

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing's Sarcoma and FET-Rearranged Sarcomas

Aug 22, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing's Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcript

Aug 8, 2022, 2:54 PM EDT - 3 years ago

Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcript

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 8, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Aug 4, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

jsmith14
jsmith14 Dec. 24 at 9:42 PM
$SLRX Santa Claus is coming to town!
0 · Reply
ABAdude
ABAdude Dec. 24 at 7:01 PM
$SLRX Hang in there longs. There is zero real capitulation occurring. Cost basis must move and profited shares ⬆️ . These are a couple of indicators that would show that real holders are selling and new buyers absorbing shares, thus lowering the cost basis. 😉
0 · Reply
Eddie5150
Eddie5150 Dec. 24 at 6:21 PM
$SLRX
0 · Reply
ABAdude
ABAdude Dec. 24 at 4:25 PM
$SLRX The 2nd image represents how most holders are underwater and would be selling for major losses on a daily basis, as this stock has been selling off daily. This appears more like MM selling shares they don’t own fo liquidity. This will show as outflow, not longs exiting (“The Game”) Short sales - short exempt orders - internal dark pool trades count as outflow immediately. While any inflow from retail is fragmented, happens in small orders, not fully registering as inflow; therein lies the illusion of selling, though it’s all synthetic and not holder capitulation. If this was a bearish indication and a sign of organic selling, the cost basis would shift downward and profited share % would rise. 🤔 Do we see this?? No! So many signs that indicate MMs attempting to control the narrative, but their actions soak differently to those who get it 🧠. Informations purposes only!
2 · Reply
ABAdude
ABAdude Dec. 23 at 5:55 PM
$SLRX Just dropping this off here. Thought some may be interested to see this stat and how it’s not being reflected in the price action. High CTB, low float, manipulated price action. 🤔
0 · Reply
Skywalker86
Skywalker86 Dec. 23 at 3:52 PM
$SLRX CTB 627% | only 95k shares available | ~5.8M float Top-10 highest borrow on ChartExchange. This is the same supply squeeze setup $AFJK before its +130% rip. Shorts paying 600%+ with no borrow cushion = any volume spike can force cover.
2 · Reply
doubleyou2
doubleyou2 Dec. 23 at 2:21 PM
$SLRX 627% !!
0 · Reply
UpWeGo11
UpWeGo11 Dec. 23 at 12:25 AM
$SLRX all them 6s do something then
0 · Reply
jeco
jeco Dec. 22 at 6:09 PM
$SLRX Borrow Fee has gone back up! 🤔
1 · Reply
doubleyou2
doubleyou2 Dec. 22 at 5:53 PM
$SLRX Sell now -> Cry later. No balls, no glory.
1 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Dec. 22 at 3:21 PM
$SLRX 💰💰💰⏳👇
0 · Reply
GemXtrades
GemXtrades Dec. 22 at 3:05 PM
$SLRX Something will happen here soon
2 · Reply
Skywalker86
Skywalker86 Dec. 22 at 2:54 PM
$SLRX 👀 $PRPH $SIDU
0 · Reply
doubleyou2
doubleyou2 Dec. 19 at 7:00 PM
$SLRX Don't be shy. You can do it. Just move that bid to .70
1 · Reply
doubleyou2
doubleyou2 Dec. 19 at 5:56 PM
$SLRX A Decoy FYI "Decoy is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the BARDA through BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response."
0 · Reply
doubleyou2
doubleyou2 Dec. 19 at 5:51 PM
$SLRX I expect a sudden push to above a dollar. Dec 31, 2025 Bye 2025 to Hello 2026 "The required quorum for the transaction of business at the Annual Meeting is 34% of the outstanding shares entitled to vote. There was less than the required voting power represented in person or by proxy at the meeting. The Annual Meeting will be reconvened on December 31, 2025 at 10.00 a.m. Central Time and will continue to be held virtually via live webcast at www.virtualshareholdermeeting.com/SLRX2025. The record date for determination of stockholders entitled to vote at the reconvened Annual Meeting remains the close of business on October 24, 2025. At the time the Annual Meeting was adjourned, proxies had been submitted by stockholders representing approximately 30% of the shares of the Company's common stock issued and outstanding as of the record date."
1 · Reply
GameArcher
GameArcher Dec. 19 at 5:38 PM
$SLRX Quorem — funny. How about you dirtbags take this stock back up and you can have the shares you need to vote. This was supposed to squeeze from $3 to $12. Instead you destroyed retail and brought it down to $.68. Terrible. Now you can pay me. And I like the 200 SMA at $8.
0 · Reply
doubleyou2
doubleyou2 Dec. 19 at 4:06 PM
$SLRX SALARIUS PHARMACEUTICALS, INC. Meeting of Stockholders Quorum not met. Meeting adjourned.
0 · Reply
Caveman25
Caveman25 Dec. 19 at 4:01 PM
The 2020 interview with Lex Fridman laid the conceptual groundwork for what we see in the $SLRX (Decoy) merger today. In 2020, Langer spoke about the theoretical potential of using engineering to "gate" how medicine enters the body; in 2025, he is actively steering $SLRX’s new platform to apply that theory to treat multi-strain viruses and difficult-to-target cancers. https://youtu.be/9LQffCdHHlQ?si=8jicP4xNoSPpUxaa
0 · Reply
Caveman25
Caveman25 Dec. 19 at 12:43 PM
$SLRX
0 · Reply
Aminovich007
Aminovich007 Dec. 19 at 11:17 AM
$SLRX Still holding
0 · Reply
doubleyou2
doubleyou2 Dec. 19 at 9:09 AM
$SLRX On Nov 11, 2025 they went into an offering. With warrants, exercisable at $1.50. Quote from that filing: "Immediately after closing the Offering, there were 4,231,846 shares of Common Stock outstanding and pre-funded warrants to acquire an additional 2,152,331 shares of Common Stock." So I believe this number is the correct one, as it is the latest one that i can find in official filings. Normally no additional warrants are exercised since date, as we are far under the $1.50 exercise price. So current market cap is 4,231,846 * 0.66 = 2,793,018.36 Strong buy at this price. Way undervalued.
0 · Reply